TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Rating) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 1,470,000 shares, an increase of 94.1% from the April 30th total of 757,300 shares. Based on an average trading volume of 658,700 shares, the short-interest ratio is currently 2.2 days. Approximately 19.3% of the company’s shares are short sold.
NASDAQ TXMD opened at $2.14 on Friday. TherapeuticsMD has a one year low of $1.99 and a one year high of $69.50. The company’s 50 day moving average price is $11.40 and its 200 day moving average price is $16.25. The firm has a market capitalization of $18.55 million, a price-to-earnings ratio of -0.10 and a beta of 2.09.
TherapeuticsMD (NASDAQ:TXMD – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($5.69) EPS for the quarter, missing the consensus estimate of ($3.50) by ($2.19). During the same quarter in the previous year, the firm posted ($5.50) EPS. As a group, sell-side analysts anticipate that TherapeuticsMD will post -10.27 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the business. Spire Wealth Management acquired a new stake in TherapeuticsMD in the fourth quarter valued at approximately $25,000. Point72 Hong Kong Ltd acquired a new stake in TherapeuticsMD in the third quarter valued at approximately $27,000. Janus Henderson Group PLC acquired a new stake in TherapeuticsMD in the third quarter valued at approximately $28,000. Centiva Capital LP acquired a new stake in TherapeuticsMD in the third quarter valued at approximately $30,000. Finally, Macquarie Group Ltd. acquired a new stake in TherapeuticsMD in the third quarter valued at approximately $37,000. 33.91% of the stock is owned by institutional investors.
TherapeuticsMD Company Profile (Get Rating)
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
- Get a free copy of the StockNews.com research report on TherapeuticsMD (TXMD)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.